Could your voice reveal hidden burnout? a new study investigates

NCT ID NCT07780812

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This study explores whether speech and voice characteristics can serve as early indicators of burnout and stress in healthcare workers. Researchers will analyze voice samples from 200 physicians, nurses, and other clinical staff, alongside standard burnout surveys. Participants will also use a handheld device called CalmiGo three times daily for 12 weeks to see if it helps manage stress. The goal is to determine if voice analysis could become a practical tool for detecting burnout.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CalmiGo device
What this could lead to
If successful, this could lead to a simple, non-invasive way to detect burnout early in healthcare workers, potentially enabling timely support and intervention.
What could go wrong
This is an early-stage exploration, and voice biomarkers may not reliably correlate with burnout. The study is limited to one institution, so results may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Aim 1 Inclusion Criteria: 1. Adult individuals (18 years-old or older) 2. Healthcare workers (physicians, nurses, advanced practice providers, and other clinical staff) at the Minneapolis Heart Institute 3. Ability to use the CalmiGo device for 12-weeks 4. Willingness to complete study questionnaires, have speech and voice samples recorded and analyzed at the beginning of the study. AIM 2 Inclusion criteria 1. Adult individuals (18 years-old or older) 2. Healthcare workers (physicians, nurses, advanced practice providers, and other clinical staff) with burnout (Mini-Z 2.0 single item burnout score 3, 4 or 5 on 5 choice item, question 2). 3. Ability to use the CalmiGo device for 12-weeks 4. Willingness to complete study questionnaires, have speech and voice samples recorded and analyzed at the beginning and end of the study. AIM 1 and 2Exclusion Criteria: 1. English is not their preferred language 2. Current or known history of a voice or speech disorder 1. Current or history of laryngeal malignancy 2. History of laryngeal surgery 3. Known diagnosis of a voice disorder: Vocal Cord Nodules, Polyp, or Cyst; Vocal Cord Paralysis; Dysphonia 4. Laryngitis 5. Dyslexia 6. Muscle Tension 7. Aphasia 8. Stuttering 9. Dysarthria 10. Essential Tremor 11. Neurodegenerative conditions (Parkinson's Disease, Multiple Sclerosis, ALS, MSA, Dementia) 12. Severe psychiatric disorder (depression, anxiety, bipolar, schizophrenia, etc.)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Burnout are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Burnout, Psychological

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Minneapolis Heart Institute

    RECRUITING

    Minneapolis, Minnesota, 55407, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.